

Estonia

Human Papillomavirus and Related Cancers, Fact Sheet 2023 (2023-03-10)



I. Key data on HPV and HPV-related cancers



Estonia has a population of 591,271 women ages 15 years and older who are at risk of developing cervical cancer. Current estimates indicate that every year 196 women are diagnosed with cervical cancer and 62 die from the disease. Cervical cancer ranks as the 5th most frequent cancer among women in Estonia and the 2nd most frequent cancer among women between 15 and 44 years of age. Data is not yet available on the HPV burden in the general population of Estonia. However, in Northern Europe, the region Estonia belongs to, about 4.2% of women in the general population are estimated to harbour cervical HPV-16/18 infection at a given time, and 77.0% of invasive cervical cancers are attributed to HPVs 16 or 18.

Cervical cancer ranks as the 5th most frequent cancer among women in Estonia and the 2nd most frequent cancer among women between 15 and 44 years of age. Data is not yet available on the HPV burden in the general population of Estonia. However, in Northern Europe, the region Estonia belongs to, about 4.2% of women in the general population are estimated to harbour cervical HPV-16/18 infection at a given time, and 77.0% of invasive cervical cancers are attributed to HPVs 16 or 18.

Table 1. Crude incidence rates of HPV-related cancers

	Male	Female
Cervical cancer	-	28.1
Anal cancer	0.80	2.29
Vulva cancer	-	3.15
Vaginal cancer	-	1.15
Penile cancer	1.75	-
Oropharyngeal cancer	3.66	0.57
Oral cavity cancer	8.43	4.15
Laryngeal cancer	9.23	1.00

Table 2. Burden of cervical cancer

	Incidence	Mortality
Annual number of new cases/deaths	196	62
Crude rate	28.1	8.88
Age-standardized rate	18.5	4.33
Cumulative risk 0-74 years (%)	1.86	0.49
Ranking of cervical cancer (all years)	5th	8th
Ranking of cervical cancer (15-44 years)	2nd	2nd

Table 3. Burden of cervical HPV infection Estonia

	No. Tested	% (95% CI)
HPV 16/18 prevalence:		
Normal cytology	-	-
Low-grade cervical lesions	-	-
High-grade cervical lesions	-	-
Cervical cancer	-	-

Figure 1. Comparison of the ten most frequent HPV oncogenic types in Estonia among women with and without cervical lesions



Estonia

Human Papillomavirus and Related Cancers, Fact Sheet 2023 (2023-03-10)



II. Complementary data on cervical cancer prevention

Table 4. Factors contributing to cervical cancer (co-factors)

Smoking prevalence (%) [95% UI], women	20.4 [15.9-25.1]
Total fertility rate (live births per women)	1.7
Hormonal contraception use (%)	19.0
HIV prevalence (%) [95% UI] (15-49 years)	0.6 [0.5-0.6]

Table 5. Sexual behaviour

MEN	
Percentage of 15-year-old who have had sexual intercourse	20.0
Range of median age at first sexual intercourse	17.4 - 18.6
WOMEN	
Percentage of 15-year-old who have had sexual intercourse	21.0
Range of median age at first sexual intercourse	15.0 - 20.2


Table 6. HPV vaccine introduction

Females	
HPV vaccination programme	Introduced
Year of introduction	2018
Year of estimation	2021
HPV coverage – first dose (%)	64
HPV coverage – last dose (%)	57
Males	
HPV vaccination programme	Not Available/Not Introduced
Year of introduction	-
Year of estimation	-
HPV coverage – first dose (%)	-
HPV coverage – last dose (%)	-

Table 7. Cervical screening practices and recommendations

Existence of official national recommendations	Yes
Starting year of recommendations	2015
Active invitation to screening	Yes
Screening ages (years), primary screening test used, and screening interval or frequency of screenings	30-59 (cytology, 5 years)

Figure 2. Estimated coverage of cervical cancer screening in Estonia*



* Estimated coverage and 95% confidence interval in 2019

Contact information:

ICO/IARC HPV Information Centre
 Institut Català d'Oncologia
 Avda. Gran Via de l'Hospitalet, 199-203
 08908 L'Hospitalet de Llobregat (Barcelona, Spain)
info@hpvcentre.net
www.hpvcentre.net